LINC00857 and ovarian cancer: In conclusion, LINC00857 regulates ovarian cancer progression and glycolysis via sponging miR‐486‐5p to upregulate YAP1 by modulating the Hippo signaling pathway, which may provide the new idea for curing ovarian cancer.